CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,976,580
- in 4 filings, $5.0M under 10b5-1 plans
Net −$4,976,580. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-06 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Grant or award | +700 | 8,685 | ||
| 2026-10-06 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Grant or award · Stock Option (Right to Buy) | +675 | 675 | ||
| 2026-05-07 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Shares withheld for taxes | −334 | $126.43 | $42K | 7,985 |
| 2026-03-02 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Shares withheld for taxes | −221 | $124.97 | $28K | 8,319 |
| 2025-12-31 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Grant or award | +2,288 | 8,540 | ||
| 2025-12-31 | Douglass Brian Robb CHIEF PRODUCT OFFICER | Grant or award · Stock Option (Right to Buy) | +2,143 | 2,143 |
Page 1 of 1 · 6 trades